Market Overview

Perrigo Buys Rosemont Pharma for $283M

Share:
Related PRGO
Deutsche Bank Boosts Mylan's Price Target On This Scenario
Worst Performing Industries For April 24, 2015
Mylan 'Raises' Perrigo Bid, But Teva Buzz Builds (Investor's Business Daily)

Perrigo Company (Nasdaq: PRGO) today announced that it has signed a definitive merger agreement and has completed the acquisition of Leeds, U.K.-based Rosemont Pharmaceuticals Ltd. ("Rosemont") for approximately £180 million or $283 million in cash.

Key benefits of the transaction include:

o Attractive Specialty Market: Rosemont's portfolio of liquid formulations addresses a critical medicinal need within pediatrics, as well as for those patients with dysphagia (swallowing difficulties), a common malady in a growing elderly population. o Immediate Access to Oral Liquid Formulations: The transaction is aligned with Perrigo's strategic growth objective to expand into additional liquid categories and diversified prescription medicines to further broaden its customer product portfolio. o Leadership Position in Sizeable and Growing Market: Favorable demographic drivers have been increasing demand for easier to swallow products. Rosemont's leading position in this market today, combined with its robust pipeline portfolio and access to under-penetrated international markets, represents an exciting opportunity for future growth and European expansion. o Synergy Opportunity: The acquisition allows Perrigo to expand its U.K. portfolio while leveraging its established distribution and administrative infrastructures and long standing customer relationships.

Posted-In: News M&A

 

Related Articles (PRGO)

Around the Web, We're Loving...